0001665124-26-000002.txt : 20260114 0001665124-26-000002.hdr.sgml : 20260114 20260114164507 ACCESSION NUMBER: 0001665124-26-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260112 FILED AS OF DATE: 20260114 DATE AS OF CHANGE: 20260114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nagendran Sukumar CENTRAL INDEX KEY: 0001665124 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 26533736 MAIL ADDRESS: STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD STREET 2: SUITE 160 CITY: BANNOCKBURN STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 form4-01142026_040101.xml X0508 4 2026-01-12 0001806310 Taysha Gene Therapies, Inc. TSHA 0001665124 Nagendran Sukumar C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 true true false false President and Head of R&D 1 Common Stock 2026-01-12 4 M 0 111324 0.6989 A 1117763 D Common Stock 2026-01-12 4 M 0 88676 1.71 A 1206439 D Common Stock 2026-01-12 4 S 0 200000 4.71 D 1006439 D Common Stock 2026-01-12 4 A 0 427000 0 A 1433439 D Employee Stock Option (right to buy) 0.6989 2026-01-12 4 M 0 111324 0 D 2033-12-14 Common Stock 111324 111359 D Employee Stock Option (right to buy) 1.71 2026-01-12 4 M 0 88676 0 D 2034-01-02 Common Stock 88676 474941 D Employee Stock Option (right to buy) 4.86 2026-01-12 4 A 0 274000 0 A 2036-01-12 Common Stock 274000 274000 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2026-01-14